Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine™ L3 adjuvant protects against tuberculosis

Vaccine

Volumn 22, Issue 11-12, 2004, Pages 1498-1508

  Haile, M ^a,b   Schroder U ^c   Hamasur, B ^a   Pawlowski, A ^a   Jaxmar, T ^a   Kallenius G ^a,b   Svenson, S B ^a,d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Karolinska Science Park   (Sweden)

^d SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

BCG; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; EUROCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IN VITRO STUDY; INFECTION PREVENTION; MOUSE; MOUSE STRAIN; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVACCINATION; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BCG VACCINE; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SURVIVAL ANALYSIS; TUBERCULOSIS; VACCINES, INACTIVATED;

EID: 1842509011     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.016     Document Type: Article

References (30)

1. Calmette A, La vaccination contre la tuberculose. Paris: Maison et Cie. p. 250.
2. Rodriguez L.C., Diwan V.K., Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22:1993;1154-1158.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V.et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 271:1994;698-702.
4. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 346:1995;1339-1345.
5. Falero-Diaz G., Challacombe S., Banerjee D., Douce G., Boyd A., Ivanyi J. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine. 28:2000;3223-3229.
6. Lyadova I.V., Vordermeier H.M., Eruslanov E.B., Khaidukov S.V., Apt A.S., Hewinson R.G. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs. Clin. Exp. Immunol. 126:2001;274-279.
7. Hamasur B., Haile M., Pawlowski A., Schröder U., Williams A., Hatch G.et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine. 21:2003;4081-4093.
8. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immunol. 65:1997;623-629.
9. Schröder U., Svenson S.B. Nasal and parenteral immuniizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine. 17:1999;2096-2103.
10. Talbot E.A., Perkins M.D., Silva S.F.M., Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin. Infect. Dis. 24:1997;1139-1146.
11. Medina E., North R.J. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology. 93:1998;270-274.
12. McLeod R., Buschman E., Arbuckle L.D., Skamene E. Immunogenetics in the analysis of resistance to intracellular pathogens. Curr. Opin. Immunol. 7:1995;539-552.
13. Thompson-Snipes L., Skamene E., Radzioch D. Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guérin is compromised by interleukin-12 ablation. Infect. Immunol. 66:1998;5268-5274.
14. Huygen K., Abramowicz D., Vandenbussche P., Jacobs F., De Bruyn J., Kentos A.et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect. Immunol. 60:1992;2880-2886.
15. Yoshida A., Koide Y., Uchijima M., Yoshida T.O. Dissection of strain difference in acquired protective immunity against Mycobacterium bovis Calmette-Guerin bacillus (BCG): macrophages regulate the susceptibility through cytokine network and the induction of nitric oxide synthase. J. Immunol. 155:1995;2057-2066.
16. Wakeham J., Wang J., Xing Z. Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice. Infect. Immunol. 68:2000;6946-6953.
17. Weiss DW. Vaccination against tuberculosis with non-living vaccines. I. The problem and its historical background. Am Rev Respir Dis 1959;80:340-358, 495-509, 676-688.
18. Tuberculosis Program, Public Health Service, USA. Experimental studies of vaccination, allergy, and immunity in tuberculosis. 3. Effect of killed BCG vaccine. Bull WHO 1955;12:47-62.
19. Orme I.M. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J. Immunol. 138:1987;293-298.
20. Andersen P., Andersen A.B., Sorensen A.L., Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 154:1995;3359-3372.
21. Ladel C.H., Daugelat S., Kaufmann S.H.E. Immune response to Myocbacterium bovis bacille Calmette-Guerin infection in major histocompatibility class I- and II-deficient knock-out mice contribution of CD4 and CD8 T cells to acquired resistance. Eur. J. Immunol. 24:1995;377-384.
22. Orme I.M., Andersen P., Boom W.H. T cell response to Mycobacterium tuberculosis. J. Infect. Dis. 167:1993;1481-1497.
23. Flynn J.A., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U.S.A. 89:1992;12013-12017.
24. Lalvani A., Brookes R., Wilkinson R.J., Malin A.S., Patnan A.A., Andersen P.et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;270-275.
25. Stenger S., Modlin R.L. T cell mediated immunity to Mycobacterium tuberculosis. Curr. Opin. Microbiol. 2:1999;89-93.
26. Singh M., Hioe C., Qiu H., Li X.M., Wang C.Y., Koff W.et al. CTL induction using synthetic peptides delivered in emulsions-critical role of the formulation procedure. Vaccine. 15:1997;1773-1778.
27. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immunol. 62:1994;2536-2544.
28. Pal P.G., Horwitz M.A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immunol. 60:1992;4781-4792.
29. Roberts A.D., Sonnenberg M.G., Ordway D.J., Furney S.K., Brennan P.J., Belisle J.T.et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology. 85:1995;502-508.
30. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.